Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.71 |
| ▸ | CCND1 | P24385 | 4/20 | 0.71 |
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988644 | 0.87 | CDK4 (0.77) | CDK4CCND1ACHEKDM4EALDH1A1 | |
| SCHEMBL4764495 | 0.87 | CDK4 (0.77) | CDK4CCND1ACHEKDM4EALDH1A1 | |
| SCHEMBL29848541 | 0.83 | CDK4 (1.00) | CDK4CCND1ACHEKDM4EALDH1A1 | |
| SCHEMBL8120408 | 0.83 | CDK4 (1.00) | CDK4CCND1ACHEKDM4EALDH1A1 | |
| SCHEMBL257083 | 0.80 | CDK4 (0.68) | CDK4CCND1KDM4EALDH1A1HPGD | |
| SCHEMBL29385261 | 0.80 | CDK4 (0.68) | CDK4CCND1KDM4EALDH1A1HPGD | |
| SCHEMBL27165740 | 0.79 | ACHE (0.54) | CDK4CCND1ACHEKDM4EALDH1A1 | |
| SCHEMBL6026569 | 0.78 | CDK4 (0.52) | CDK4CCND1ACHECHEK1MEN1 | |
| Benzene SCHEMBL7080453 | 0.78 | CDK4 (0.66) | CDK4CCND1KDM4EALDH1A1HPGD | |
| SCHEMBL30032319 | 0.78 | CDK4 (0.53) | CDK4CCND1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512848-B1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-20190214574-A1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | MERCK PATENT GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
| WO-2018050583-A1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | MERCK PATENT GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2012163933-A1 | AMINO-SUBSTITUTED-ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE DERIVATIVES AS NEW POTENT KINASE INHIBITORS | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| WO-2011131636-A1 | COMBINED TREATMENT OF CANCER WITH BENZO[E]PYRIDOINDOLES AND DNA-DAMAGING AGENTS | INSTITUT CURIE (FR) | 2011-10-27 | — | — | WO | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | PFIZER INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | CDK4 68/4885CCND1 67/4885ACHE 4558/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | CDK4 64/4885CCND1 67/4885ACHE 4544/4885 |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | TOP2A, TOP2B, TOP1 | CDK4 106/4885CCND1 979/4885ACHE 3864/4885 |
| US-20190214574-A1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | CYCS, CYP3A4, CYP2E1 | CDK4 1097/4885CCND1 2872/4885ACHE 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.